We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research peptide — not a dietary supplement
Hexarelin is a research compound, not a regulated dietary supplement. It is typically administered by injection and sold “for research use only.” The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most Hexarelin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 1996–2003 with a typical study size of 12 participants.
Based on 9 studies · 100 total participants
Confidence
LowBy outcome
The current evidence for Hexarelin is insufficient to assign an evidence score, based on 9 indexed studies. A synthetic hexapeptide growth-hormone secretagogue (a ghrelin-receptor / GHS-R1a agonist) that triggers a sharp pituitary GH pulse. Honest appraisal: real human studies confirm it acutely raises GH, but the GH response partially DESENSITIZES (attenuates) with continued dosing, it also raises cortisol and prolactin, and there are NO body-composition or clinical outcome trials. A grey-market, research-use-only injectable — not an approved drug or a regulated dietary supplement, and WADA-banned. Representative study: PMID 10990150.
The commonly studied dose of Hexarelin is No established or approved human dose. Research studies used roughly 1-2 µg/kg IV acutely, or ~60 µg/kg intranasally / twice-daily subcutaneous injections in trials. Grey-market use is unregulated and not endorsed.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Mecasermin (IGF-1)
Mostly mechanism / observationalThe pharmaceutical-grade version of IGF-1 — an FDA/EMA-approved prescription injectable, but approved ONLY for a rare childhood growth disorder (severe primary IGF-1 deficiency / Laron syndrome), where it genuinely raises height velocity in clinical trials. It is the regulated counterpart to the grey-market igf-1-lr3 peptide bodybuilders inject, and shares the same core risks. Crucially, there is NO trial supporting its off-label use for muscle, performance, or anti-aging in healthy adults — and IGF-1's documented harms (hypoglycemia, intracranial hypertension, lymphoid/tonsillar hypertrophy, and a theoretical cancer concern because IGF-1 is mitogenic) are real. Not a dietary supplement, not a longevity drug.
Last reviewed June 2026 · evidence from 9 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Hexarelin (Examorelin)
A synthetic hexapeptide growth-hormone secretagogue (a ghrelin-receptor / GHS-R1a agonist) that triggers a sharp pituitary GH pulse. Honest appraisal: real human studies confirm it acutely raises GH, but the GH response partially DESENSITIZES (attenuates) with continued dosing, it also raises cortisol and prolactin, and there are NO body-composition or clinical outcome trials. A grey-market, research-use-only injectable — not an approved drug or a regulated dietary supplement, and WADA-banned.
Scores very low because the human evidence is short-term pharmacology only: it reliably raises GH acutely, but that response desensitizes with use and no trials show any body-composition, strength, or clinical outcome benefit.
Hexarelin (examorelin) is a synthetic enkephalin-derived hexapeptide developed in the 1990s as a growth-hormone secretagogue (GHS).
It binds the GH-secretagogue receptor GHS-R1a — the same receptor as the natural hormone ghrelin — at the pituitary and hypothalamus, and acutely evokes a large, dose-related GH pulse in humans after intravenous, subcutaneous, intranasal or even oral dosing. Two things keep the honest evidence picture modest.
First, the GH response is not durable: controlled human studies show it partially DESENSITIZES (attenuates) with continued administration — twice-daily subcutaneous hexarelin in healthy elderly subjects roughly halved the GH area-under-curve over 16 weeks (the effect was partial and reversible after a washout), and chronic intranasal dosing in children blunted the GH response within a week.
Second, hexarelin is not GH-selective: it also stimulates ACTH/cortisol and prolactin secretion.
Separately from the GH axis, hexarelin has a distinct cardiovascular pharmacology — it binds myocardial receptors and the scavenger receptor CD36, produced a GH-independent positive inotropic effect (raised left-ventricular ejection fraction) in an acute human study, and protected against post-ischemic ventricular dysfunction in animal hearts.
Crucially, all of this is short-term mechanistic / pharmacological work. There are NO trials showing hexarelin improves body composition, strength, athletic performance, or any clinical cardiac outcome in people, and its long-term safety is unknown.
It is a grey-market 'research peptide' sold for injection outside any approved medical use, carries the usual unregulated-injectable sourcing risks, and is banned by WADA. The overall evidence is best treated as UNSCORED / emerging.
Binds the GH-secretagogue receptor GHS-R1a — the ghrelin receptor — at the pituitary and hypothalamus, partly by counteracting somatostatin tone, to evoke a sharp, dose-related GH pulse.
Binds specific myocardial receptors and the scavenger receptor CD36, the basis for GH-independent cardiac effects seen in preclinical models and one acute human study.
Not GH-selective — also stimulates the hypothalamic-pituitary-adrenal axis (ACTH and cortisol) and prolactin, an off-target endocrine effect of the GHS class.
How Hexarelin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No established or approved human dose. Research studies used roughly 1-2 µg/kg IV acutely, or ~60 µg/kg intranasally / twice-daily subcutaneous injections in trials. Grey-market use is unregulated and not endorsed.
Can be taken without food
| Form | Type |
|---|---|
| 💊Subcutaneous injection (research-use only) | Recommended |
| 💊Intranasal (research-use only) | Alternative |
Grey-market peptide — not available as a regulated dietary supplement or approved drug. Quality and identity cannot be assured from research-chemical suppliers.
Minimum: 1 weeks
Optimal: 4 weeks
Cycling: Not required
Note: No validated timing. This is a research peptide with no approved indication; any dosing schedule is experimental and the GH response attenuates with repeated use.
Dose-response data unavailable. The current published research for Hexarelin does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Reliably triggers a large acute rise in growth hormone in humans — a measured biomarker effect, strongest in pubertal children and young adults, blunted in the elderly.
The GH response partially attenuates with continued dosing (≈halved over 16 weeks in healthy elderly; blunted within a week with chronic intranasal use) — partial and reversible after washout.
Stimulates ACTH/cortisol and prolactin alongside GH — an off-target endocrine effect, not a desired one.
No human trials show benefit for muscle, fat, strength, performance, or any clinical cardiac endpoint. Effects are biomarker/pharmacology only.
Avoid — not studied.
Avoid — GH/IGF-1 elevation is theoretically growth-promoting.
Prohibited — GH secretagogues are banned by WADA at all times.
Do not self-experiment; cardiovascular and glucose effects are real and unsupervised use is unsafe.
Hexarelin stimulates ACTH and cortisol; its endocrine effects interact with glucocorticoids and HPA-axis agents (e.g. blunted by dexamethasone, exaggerated in Cushing's).
GH elevation can oppose insulin action and raise glucose, theoretically working against glucose-lowering therapy.
Tip: Inherent to the GHS class; no validated mitigation — a reason not to use chronically
Tip: Off-target endocrine effect of the peptide
Tip: Partial and reversible after a washout; reflects receptor desensitization, not tolerance to a benefit
Tip: Inherent to grey-market injectables; sterility and purity are unverified
Tip: Class effect of GH elevation; not well characterized for hexarelin specifically
Timing is flexible for Hexarelin — consistent daily use matters more than the time of day. Acute GH-stimulation studies dosed IV/SC without regard to meals.
Hexarelin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are raised cortisol / ACTH, raised prolactin, attenuating GH response (desensitization). Use caution if any of these apply to you: Pregnancy and breastfeeding (not studied — avoid); Active or prior cancer (GH/IGF-1 elevation is theoretically growth-promoting); Competitive athletes subject to anti-doping testing (WADA-banned).
Insulin (bodybuilding use)
Mostly mechanism / observationalInsulin is a life-saving prescription hormone for diabetes — and, used illicitly by bodybuilders as an off-label 'anabolic,' one of the most dangerous performance drugs in existence. The theory is nutrient partitioning: insulin drives glucose and amino acids into muscle and suppresses muscle-protein breakdown. But there is NO controlled evidence that insulin builds muscle or improves performance in healthy, non-diabetic athletes — and a non-diabetic who injects it risks profound, sometimes FATAL hypoglycemia (coma, seizures, brain injury, death), plus fat gain. This is a harm-reduction reference documenting a popular, deadly misuse, NOT a recommendation and NOT a dietary supplement.
Stacking with other GHS or exogenous GH compounds compounds GH/IGF-1 elevation and its associated risks; not studied.